Why We Need to Change How We Look for Renal Cell Carcinoma Biomarkers
Proangiogenic or proimmunogenic genomic and transcriptomic signatures in the tumor microenvironment may have predictive value.
Latest Features
LATEST ARTICLES
When Patient-Reported Outcomes Could Pose Risks
During a recent conference on quality of life in patients with cancer, FDA-affiliated researchers debunked a notion about biases — but raised some concerns about PROs.
How to Help Patients With Cancer Find Trustworthy Information Online
Patients may find misinformation on websites or social media forums, but doctors can help by recommending reliable sources.
Multinational Consensus Panel Confirms Benefits of Exercise, Updates Recommendations for Cancer Survivors
The American College of Sports Medicine reconvened the ACSM Roundtable to update its guidelines for prescribing exercise for patients and survivors of cancers.
Treatment Strategies for Lymphoma in Patients With HIV
Cancer, particularly non-Hodgkin lymphoma, remains a leading cause of death in patients with HIV who are being treated with antiretroviral therapy.
Brokering Early Palliative Care: How Nurses Approached a Misunderstood Topic
Palliative care can be effectively introduced along with other treatments, and the combination of care improves patient symptoms and quality of life.
Prior Treatment Exposure May Contribute to Tumor Mutational Signature
Pretreatment significantly affected health outcomes for patients with metastatic breast cancer.
Gender Bias in Oncology: Q&A With Dr Narjust Duma
Women are less likely to be introduced by their professional title and most likely to be introduced by first name.
Increased Risk for Mental Health Disorders Seen With Head and Neck Cancers
Mental health disorders may be an adverse effect of head and neck cancer diagnosis, treatment, or treatment morbidities.
FDA Studies Assess Patient-Reported Outcomes in Lung Cancer Trials
FDA analyses find trial-to-trial variation in the analysis of patient reported outcomes, underscoring the need for standardization.
FDA Label Restriction Triggers Increased Uptake of PD-L1 Assays in Urothelial Carcinoma
FDA label changes for certain immunotherapies may have prompted a marked increase in the use of PD-L1 assays.
Ibrutinib and Hypertension in CLL: What Are the Risks?
Multiple postmarketing studies have pointed to percentages of cardiovascular-associated AEs with ibrutinib that are higher than the number outlined in the drug’s PI.
Can CAR-T Be Optimized for Multiple Myeloma?
To tweak CAR-T therapies for myeloma, researchers are trying to repurpose a failed Alzheimer’s drug and are extracting patients’ T cells sooner.
Study on Veterans Reveals Real-World Survival Outcomes for Targeted Therapies in Advanced Renal Cell Carcinoma
Findings underscore the limited generalizability of clinical trial results to patients in the real world.
Autoimmune Conditions and Primary CNS Lymphoma Risk
Primary central nervous system lymphoma (PCNSL) is a rare (incidence rate of 0.6 cases per 100,000 person years) non-Hodgkin lymphoma (NHL) found in the brain, spinal cord, and leptomeninges.
Want to read more?
Please login or register first to view this content.
